Roivant Sciences Ltd.

Listed Company

ROIVCIK 0001635088NasdaqLarge AcceleratedPharmaceutical PreparationsD0FY ends Mar 31

Period

FY 2026

Revenue

$8.26M

Net Income

$-299.77M

Total Assets

$5.71B

Equity

$4.53B

Shares Out

719.27M

Op. Cash Flow

$-750.35M

ROIV$34.52+196.56% · past yearDBEQ Basic

Daily closing prices

Business

Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through subsidiary companies called Vants, each focused on specific product candidates. The company's pipeline includes brepocitinib (small molecule JAK1/TYK2 inhibitor for autoimmune diseases), IMVT-1402 (monoclonal antibody targeting FcRn for IgG-mediated autoimmune indications), and mosliciguat (inhaled sGC activator for pulmonary hypertension). Roivant operates through subsidiaries including Priovant, Immunovant, Pulmovant and Genevant, with geographic focus on the U.S., E.U., Canada and other regions through licensing agreements.

Summary from 10-K filed 2026-05-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Revenue	8	29	33	32	55
Cost of revenues	1	911,000	2	3	9
Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)	682	550	440	454	483
Acquired in-process research and development	0	0	26	98	140
General and administrative (includes $298,297, $239,505, and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)	610	591	416	383	775
Total operating expenses	1,294	1,143	884	938	1,407
Gain on sale of Telavant net assets	0	110	5,348	0	—
Gain on litigation settlement	770	0	0	—	—
(Loss) income from operations	−515	−1,003	4,497	−907	−1,352
Change in fair value of investments	−105	−55	48	21	87
Change in fair value of liability instruments	48	−16	47	18	—
Gain on deconsolidation of subsidiaries	−11	−3	−33	−29	−5
Interest income	−178	−258	−146	—	—
Other (income) expense, net	−4	11	14	486,000	−3
(Loss) income from continuing operations before income taxes	−265	−682	4,568	−885	−924
Income tax expense	133	48	22	4	369,000
(Loss) income from continuing operations, net of tax	−398	−730	4,500	−889	−924
Income (loss) from discontinued operations, net of tax	0	373	−315	−226	0
Net (loss) income	−398	−357	4,231	−1,115	−924
Net loss attributable to noncontrolling interests	−98	−185	−118	−106	−79
Net (loss) income attributable to Roivant Sciences Ltd.	−300	−172	4,349	−1,009	−845
(Loss) income from continuing operations, net of tax	−300	−545	4,663	−784	−845
Income (loss) from discontinued operations, net of tax	0	373	−314	−225	0
(Loss) income from continuing operations, net of tax (in dollars per share)	−0.43	−0.75	5.95	−1.1	−1.26
Income (loss) from discontinued operations, net of tax (in dollars per share)	0	0.51	−0.4	−0.32	0
Net (loss) income (in dollars per share)	−0.43	−0.24	5.55	−1.42	−1.26
(Loss) income from continuing operations, net of tax (in dollars per share)	−0.54	−0.75	5.61	−1.1	−1.26
Income (loss) from discontinued operations, net of tax (in dollars per share)	0	0.51	−0.38	−0.32	0
Net (loss) income (in dollars per share)	−0.54	−0.24	5.23	−1.42	−1.26
Basic (in shares)	694	725	783	713	670
Diluted (in shares)	694	725	831	713	670

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	1,419	2,715	6,495	1,677	2,060
Marketable securities (held at fair value as of March 31, 2026)	2,873	2,171	0	—	—
Litigation settlement receivable	770	0	—	—	—
Other current assets	105	113	81	122	86
Total current assets	5,167	5,000	6,732	1,799	2,147
Property and equipment, net	12	12	15	39	26
Operating lease right-of-use assets	80	89	44	53	61
Investments measured at fair value	408	303	248	304	326
Other assets	41	33	38	49	26
Total assets	5,709	5,437	7,222	2,390	2,585
Accounts payable	18	24	14	38	35
Accrued expenses	206	114	119	167	128
Operating lease liabilities	11	10	9	12	11
Income tax payable	46	416,000	—	—	—
Other current liabilities	583,000	1	14	15	11
Total current liabilities	281	149	267	272	184
Liability instruments measured at fair value	0	10	26	64	45
Operating lease liabilities, noncurrent	96	90	45	53	62
Income tax payable, noncurrent	39	0	—	—	—
Other liabilities	70,000	22,000	2	17	22
Total liabilities	416	250	774	782	524
Commitments and contingencies (Note 12)	—	—	—	—	—
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 720,352,386 and 695,938,323 shares issued and outstanding at March 31, 2026 and 2025, respectively	0	0	0	0	0
Additional paid-in capital	5,025	4,562	5,396	4,933	4,422
(Accumulated deficit) / retained earnings	−502	116	576	−3,773	−2,764
Accumulated other comprehensive income	4	9	−4	−3	−946,000
Shareholders equity attributable to Roivant Sciences Ltd.	4,527	4,688	5,969	1,158	1,657
Noncontrolling interests	765	500	480	450	382
Total shareholders equity	5,292	5,187	6,449	1,608	2,039
Total liabilities and shareholders equity	5,709	5,437	7,222	2,390	2,585

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Change in fair value of debt and liability instruments	48	−113	79	78	—
Gain on sale of subsidiary interests	0	−377	0	0	—
Impairment loss on operating lease right-of-use assets	16	0	0	—	—
Accretion of discount and amortization of premium on available-for-sale marketable securities, net	−23	0	0	—	—
Accretion of discount and amortization of premium on held-to-maturity marketable securities, net	−14	−70	0	—	—
Realized gain from sales of marketable securities	−976,000	0	0	—	—
Loss on extinguishment of debt	0	9	0	0	—
Depreciation and amortization	3	14	22	19	6
Non-cash lease expense	8	7	7	8	7
Other	2	4	10	−21	617,000
Other current assets	11	−25	−81	−32	−28
Other assets	−7	−9	16	−17	—
Litigation settlement receivable	−770	0	0	—	—
Accounts payable	3	−18	23	4	15
Accrued expenses	59	−10	40	39	51
Operating lease liabilities	−2	−6	−8	−9	−7
Accrued interest	0	0	22	19	—
Income tax payable	85	−10	10	—	—
Other liabilities	−1	773,000	−2	2	—
Net cash used in operating activities	−750	−839	−765	−843	−678
Purchases	−4,796	0	0	—	—
Proceeds from maturities	1,122	0	0	—	—
Proceeds from sales	821	0	0	—	—
Purchases	0	−4,062	0	—	—
Proceeds from maturities	2,185	1,960	0	—	—
Proceeds from sale of Telavant net assets, net	0	110	5,233	0	—
Proceeds from sale of subsidiary interests	0	261	48	0	—
Cash decrease upon deconsolidation of subsidiaries	−4	−31	−84	−7	−39,000
Purchase of property and equipment	−8	−5	−1	−13	−17
Other	−3	79,000	9	702,000	600,000
Net cash (used in) provided by investing activities	−682	−1,766	5,204	−44	303
Proceeds from issuance of the Companys common shares, net of issuance costs paid	0	0	200	312	0
Proceeds from issuance of subsidiary common shares, net of issuance costs paid	194	113	239	—	—
Repayment of debt by subsidiary	0	−52	−29	−29	−22
Proceeds from exercise of the Companys and subsidiary stock options	268	50	54	3	412,000
Taxes paid related to net settlement of equity awards	−49	−37	−38	−11	0
Proceeds from issuance of the Companys common shares under employee stock purchase plan	1	1	951,000	316,000	0
Payments on principal portion of finance lease obligations	0	−774,000	−2	−692,000	0
Payment of subsidiary dividend	0	0	−6	0	—
Proceeds from exercise of the Companys warrants	0	0	5,000	0	—
Payment for redemptions of the Companys warrants	0	0	−41,000	0	—
Net cash provided by (used in) financing activities	134	−1,220	419	499	307
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4	747,000	616,000	6	—
Net change in cash, cash equivalents and restricted cash	−1,295	−3,825	4,858	−382	−68
Cashless exercise of the Companys warrants	0	0	83	0	—
Issuance of subsidiary shares in connection with debt renegotiation	0	12	0	0	—
Operating lease right-of-use assets obtained and exchanged for operating lease liabilities	10	51	2	4	—
Reclassification of earn-out shares liability to additional paid-in capital upon vesting	58	0	0	—	—
Taxes payable related to net settlement of equity awards	31	0	0	—	—
Other	3	59,000	441,000	7	6
Interest paid	0	6	10	5	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Roivant Sciences Ltd.'s CIK number?

Roivant Sciences Ltd.'s SEC CIK number is 0001635088 (1635088). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Roivant Sciences Ltd.'s SEC filings?

All of Roivant Sciences Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Roivant Sciences Ltd. last report earnings?

Roivant Sciences Ltd. (ROIV) most recently filed an earnings 8-K with the SEC on May 20, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001635088-26-000060). This is Roivant Sciences Ltd.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Roivant Sciences Ltd.'s most recent earnings 8-K?

Roivant Sciences Ltd.'s latest earnings 8-K (Item 2.02) was filed May 20, 2026 under accession 0001635088-26-000060. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Roivant Sciences Ltd.'s latest earnings 8-K →
Look up any company's CIK number →